| |
|
Product Name:
|
Herpes simplex virus 1
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Virus Classification: Orthoherpesviridae, Simplexvirus
Species: Human alphaherpesvirus 1 (herpes simplex virus 1)
Strain/Isolate: KOS derivative, drug-resistant pol mutant PAAr5 (R842S)
|
|
Additional Information:
|
HSV-1, KOS is a laboratory-adapted strain that was originally isolated from a lip lesion of a human in 1964 and has been used as starting material for a variety of HSV-1 mutant strains.4 The complete genome of HSV-1, KOS has been sequenced (GenBank: JQ673480 and KT899744).
Herpes simplex virus 1 and 2 cause frequent human infections, with worldwide prevalence reported at 67% and 13%, respectively.5 They belong to the family Orthoherpesviridae. It is a large enveloped double stranded DNA (approximately 152000 base pairs) virus, with an icosahedral capsid and tegument layer.5
|
|
Material Provided:
|
Each vial contains approximately 1 mL of cell lysate and supernatant from Chlorocebus aethiops kidney epithelial cells, clone 6 infected with HSV-1, KOS derivative, drug-resistant pol mutant PAAr5 (R842S).
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-59960 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Host: Chlorocebus aethiops kidney epithelial cells, clone 6 (Vero E6; ATCC® CRL-1586™)
Growth Medium: Eagle’s Minimum Essential Medium containing Earle’s Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1.5 g/L of sodium bicarbonate supplemented with 2% fetal bovine serum, or equivalent
Infection: Cells should be 60% to 80% confluent
Recommended Seeding Concentration: 3.5 to 4 × 104 cells/cm2
Incubation: 3 to 6 days at 37°C and 5% CO2
Cytopathic Effect: Refractile rounding
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Coen, D. M., Personal Communication.
2. Jofre, J., P. Schaffer, and D. S. Parris. “Genetics of Resistance to Phosphonoacetic Acid in Strain KOS of Herpes Simplex Virus Type 1.” J. Virol. 3 (1977): 833-836. PubMed: 197275.
3. Gibbs, J. S., et al. “Identification of Amino Acids in Herpes Simplex Virus DNA Polymerase Involved in Substrate and Drug Recognition.” Proc. Natl. Acad. Sci. USA 85 (1988): 6672-6676.
4. Colgrove, R. C., et al. “History and Genomic Sequence Analysis of the Herpes Simplex Virus 1 KOS and KOS1.1 Sub-Strains.” Virology 487 (2016): 215-221. PubMed: 26547038.
5. Zhu, S. and A. Viejo-Borbolla. “Pathogenesis and Virulence of Herpes Simplex Virus.” Virulence 12 (2016): 2670-2702. PubMed: 34676800.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Herpes Simplex Virus 1, KOS Derivative, Drug-Resistant pol Mutant PAAr5 (R842S), NR-59960.”
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|